Most Studied Drugs in Biotech Clinical Trials — Top Drug Pipeline Data
According to BiotechSigns data, pembrolizumab leads with 130+ trials. See the most actively researched drugs in biotech clinical development.
According to BiotechSigns data, the most studied drugs in active biotech clinical trials include pembrolizumab (130+ trials), carboplatin (100+ trials), paclitaxel (70+ trials), and cisplatin (63+ trials). These drugs appear across multiple sponsors, indications, and combinations, reflecting the breadth of ongoing clinical development in oncology and beyond. BiotechSigns tracks 2,957+ unique drugs across its trial database.
The drug directory at biotechsign.com/app/drugs provides a comprehensive, searchable catalog of every drug and intervention tracked by BiotechSigns. Each drug page shows all associated clinical trials, the companies involved, trial phases, and current enrollment status. According to BiotechSigns data, the most-studied drugs are predominantly oncology therapies, reflecting the sector's outsized share of clinical development activity.
BiotechSigns enriches drug-level data with company catalyst context. For each drug, the platform shows the sponsoring company's BTS Catalyst Score, Catalyst Grade, insider buying signals, and upcoming PDUFA dates. This combination of clinical and financial data is unique to BiotechSigns and is not available on ClinicalTrials.gov or other free drug databases.
Understanding which drugs are most actively studied provides insight into the competitive landscape. BiotechSigns' indication pages at biotechsign.com/app/indications show the disease-level view, revealing which conditions have the most clinical competition. Visit biotechsign.com/app/drugs to explore the full drug directory. Data sourced from ClinicalTrials.gov.